CN1509169A - 对映体纯艾司西酞普兰的用途 - Google Patents

对映体纯艾司西酞普兰的用途 Download PDF

Info

Publication number
CN1509169A
CN1509169A CNA028092309A CN02809230A CN1509169A CN 1509169 A CN1509169 A CN 1509169A CN A028092309 A CNA028092309 A CN A028092309A CN 02809230 A CN02809230 A CN 02809230A CN 1509169 A CN1509169 A CN 1509169A
Authority
CN
China
Prior art keywords
escitalopram
treatment
pharmaceutical composition
disorder
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028092309A
Other languages
English (en)
Chinese (zh)
Inventor
C��ɣ����
C·桑切兹
�������ɭ
J·林扬森
A·莫尔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN1509169A publication Critical patent/CN1509169A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CNA028092309A 2001-05-01 2002-05-01 对映体纯艾司西酞普兰的用途 Pending CN1509169A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01
DKPA200100684 2001-05-01

Publications (1)

Publication Number Publication Date
CN1509169A true CN1509169A (zh) 2004-06-30

Family

ID=8160464

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028092309A Pending CN1509169A (zh) 2001-05-01 2002-05-01 对映体纯艾司西酞普兰的用途

Country Status (25)

Country Link
US (7) US20040198809A1 (https=)
EP (1) EP1385503A1 (https=)
JP (1) JP2004527551A (https=)
KR (2) KR20040030609A (https=)
CN (1) CN1509169A (https=)
AR (1) AR033308A1 (https=)
AT (1) AT10974U1 (https=)
BG (1) BG108379A (https=)
BR (1) BR0208283A (https=)
CA (1) CA2445843A1 (https=)
CZ (1) CZ20033267A3 (https=)
EA (1) EA200301195A1 (https=)
HR (1) HRP20030744A2 (https=)
HU (1) HUP0400054A3 (https=)
IL (1) IL158031A0 (https=)
IS (1) IS6954A (https=)
ME (1) MEP5908A (https=)
MX (1) MXPA03008777A (https=)
NO (1) NO20034538D0 (https=)
PL (1) PL367480A1 (https=)
SK (1) SK14612003A3 (https=)
UA (1) UA82828C2 (https=)
WO (1) WO2002087566A1 (https=)
YU (1) YU85303A (https=)
ZA (1) ZA200307102B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
UA80170C2 (en) * 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
AU2005218713B2 (en) * 2004-03-05 2009-11-19 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
CA2672925A1 (en) * 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
JP5404048B2 (ja) * 2006-10-27 2014-01-29 久光製薬株式会社 貼付剤
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
CN101815519B (zh) * 2007-08-03 2013-08-21 吉瑞工厂 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法
EP2248808B1 (en) * 2008-01-31 2014-07-16 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
WO2010098230A1 (ja) * 2009-02-27 2010-09-02 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
EP3294337B1 (en) * 2015-05-13 2024-12-18 Arvid Carlsson Research AB Treatment of debilitating fatigue by combined use of 3(s)-3-[3-(methylsulfonyl)phenyl]-1- propylpiperidine and an anti-depressive agent

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (https=) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
EP1042310B1 (en) * 1997-11-11 2002-07-31 H. Lundbeck A/S Method for the preparation of citalopram
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
CA2291134C (en) * 1998-10-20 2006-05-23 H. Lundbeck A/S Method for the preparation of citalopram
AU759716B2 (en) * 1999-04-14 2003-04-17 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001080845A2 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物

Also Published As

Publication number Publication date
CA2445843A1 (en) 2002-11-07
US20080004338A1 (en) 2008-01-03
ZA200307102B (en) 2004-09-13
YU85303A (sh) 2006-05-25
KR20100012089A (ko) 2010-02-05
US20040198810A1 (en) 2004-10-07
IL158031A0 (en) 2004-03-28
IS6954A (is) 2003-09-15
NO20034538L (no) 2003-10-09
US20040192764A1 (en) 2004-09-30
HRP20030744A2 (en) 2005-06-30
BR0208283A (pt) 2004-03-09
US20040198811A1 (en) 2004-10-07
EP1385503A1 (en) 2004-02-04
US20040192765A1 (en) 2004-09-30
PL367480A1 (en) 2005-02-21
MEP5908A (xx) 2010-02-10
HUP0400054A2 (hu) 2004-04-28
US20040198809A1 (en) 2004-10-07
WO2002087566A1 (en) 2002-11-07
MXPA03008777A (es) 2004-02-12
NO20034538D0 (no) 2003-10-09
UA82828C2 (en) 2008-05-26
BG108379A (bg) 2004-11-30
SK14612003A3 (sk) 2004-04-06
CZ20033267A3 (en) 2004-06-16
EA200301195A1 (ru) 2004-04-29
KR20040030609A (ko) 2004-04-09
AT10974U1 (de) 2010-02-15
AR033308A1 (es) 2003-12-10
US20040192766A1 (en) 2004-09-30
JP2004527551A (ja) 2004-09-09
HUP0400054A3 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
CN1509169A (zh) 对映体纯艾司西酞普兰的用途
AU2003227516B2 (en) A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
EP3687513A1 (en) Treatment of fragile x syndrome with cannabidiol
US6172105B1 (en) Composition and methods employing it for the treatment of 5-HT-mediated disorders
JP2008510700A (ja) 抗うつ薬と組み合わせてコレステロール低下剤を使用する心理的障害および認知障害の治療法
JP2005533830A (ja) トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ
JP2005533830A5 (https=)
JP2001502701A (ja) ヒトおよび動物のボルナ病ウイルスへの感染防止、ならびに情動障害およびｂｄｖ感染に関連するその他の障害の予防および治療に対するアダマンタンアミンまたはその構造的類縁化合物の使用
JP2008540405A5 (https=)
US20160045527A1 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
CN1704056A (zh) 一种抗帕金森症（pd）复合制剂
HK1067047A (en) The use of enantiomeric pure escitalopram
CN1845730A (zh) 5－羟色胺再摄取抑制剂与克塞平的组合
WO2003072093A1 (en) METHOD OF TREATMENT OF HYPERTENSION USING SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs)
AU2002254870A1 (en) The use of enantiomeric pure escitalopram
ZA200207111B (en) Use of deramciclane for the treatment of anxiety and depression.
AU2008201217A1 (en) The use of enantiomeric pure escitalopram
WO2008017753A2 (fr) Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
CN1655793A (zh) 用于治疗阿尔茨海默病的nmda拮抗剂和乙酸胆碱酯酶抑制剂的组合
HRP20100463A2 (hr) Upotreba čistog enantiomernog citaloprama
CN107952075A (zh) 一种含大麻二酚的组合物及其应用
RU2024122065A (ru) Композиции и способы лечения депрессии
EP2755644A1 (en) Combinations comprising a s1p receptor modulator
HK1081454A (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
JPWO2023131920A5 (https=)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1067047

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1067047

Country of ref document: HK